Acute megakaryoblastic leukemia other diagnostic studies: Difference between revisions
(Added radiographic features) |
No edit summary |
||
Line 16: | Line 16: | ||
*The [[immunophenotype]] was detected by [[flow cytometry]] and [[immunohistochemistry]] assay.<ref name="pmid17605859">{{cite journal |author=Lei Q, Liu Y, Tang SQ |title=[Childhood acute megakaryoblastic leukemia] |language=Chinese |journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi |volume=15 |issue=3 |pages=528-32 |year=2007 |pmid=17605859 |doi=}}</ref> | *The [[immunophenotype]] was detected by [[flow cytometry]] and [[immunohistochemistry]] assay.<ref name="pmid17605859">{{cite journal |author=Lei Q, Liu Y, Tang SQ |title=[Childhood acute megakaryoblastic leukemia] |language=Chinese |journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi |volume=15 |issue=3 |pages=528-32 |year=2007 |pmid=17605859 |doi=}}</ref> | ||
*In blood and bone marrow smears megakaryoblasts are usually medium sized to large cells with a high nuclear- cytoplasmic ratio. Nuclear [[chromatin]] is dense and homogeneous. There is scanty, variable basophilic cytoplasm which may be vacuolated. An irregular cytoplasmic border is often noted in some of the megakaryoblasts and occasionally projections resembling budding atypical platelets are present. | *In blood and bone marrow smears megakaryoblasts are usually medium sized to large cells with a high nuclear- cytoplasmic ratio. Nuclear [[chromatin]] is dense and homogeneous. There is scanty, variable basophilic cytoplasm which may be vacuolated. An irregular cytoplasmic border is often noted in some of the megakaryoblasts and occasionally projections resembling budding atypical platelets are present. The megakaryoblasts lack [[myeloperoxidase]] activity and stain negatively with Sudan black B (SBB). | ||
*They are alpha [[naphthyl butyrate esterase]] negative and manifest variable alpha | *They are alpha [[naphthyl butyrate esterase]] negative and manifest variable alpha naphthyl acetate esterase activity usually in scattered clumps or granules in the cytoplasm. [[PAS]] staining also varies from negative to focal or granular positivity, to strongly positive staining. | ||
*A marrow aspirate is difficult to obtain in many cases because of variable degree of [[myelofibrosis]]. | *A marrow aspirate is difficult to obtain in many cases because of variable degree of [[myelofibrosis]]. | ||
Line 24: | Line 24: | ||
*More precise identification by immunophenotyping or with [[electron microscopy]] (EM). [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61) may be diagnostic.<ref name="pmid12239137">{{cite journal |author=Vardiman JW, Harris NL, Brunning RD |title=The World Health Organization (WHO) classification of the myeloid neoplasms |journal=[[Blood]] |volume=100 |issue=7 |pages=2292-302 |year=2002 |pmid=12239137 |doi=10.1182/blood-2002-04-1199 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12239137}}</ref> | *More precise identification by immunophenotyping or with [[electron microscopy]] (EM). [[Immunophenotyping]] using MoAb to megakaryocyte restricted antigen (CD41 and CD61) may be diagnostic.<ref name="pmid12239137">{{cite journal |author=Vardiman JW, Harris NL, Brunning RD |title=The World Health Organization (WHO) classification of the myeloid neoplasms |journal=[[Blood]] |volume=100 |issue=7 |pages=2292-302 |year=2002 |pmid=12239137 |doi=10.1182/blood-2002-04-1199 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=12239137}}</ref> | ||
=== | === Karyotype analysis: === | ||
* Using Chest X-ray ('''CXR'''), '''skeletal survey''', '''CT scan''', and '''bone scan''' are: | * It helps in distinguishing due to alter karyotypic presentation (t(1;22)(p13;q13).<ref name="DöhnerEstey2010">{{cite journal|last1=Döhner|first1=Hartmut|last2=Estey|first2=Elihu H.|last3=Amadori|first3=Sergio|last4=Appelbaum|first4=Frederick R.|last5=Büchner|first5=Thomas|last6=Burnett|first6=Alan K.|last7=Dombret|first7=Hervé|last8=Fenaux|first8=Pierre|last9=Grimwade|first9=David|last10=Larson|first10=Richard A.|last11=Lo-Coco|first11=Francesco|last12=Naoe|first12=Tomoki|last13=Niederwieser|first13=Dietger|last14=Ossenkoppele|first14=Gert J.|last15=Sanz|first15=Miguel A.|last16=Sierra|first16=Jorge|last17=Tallman|first17=Martin S.|last18=Löwenberg|first18=Bob|last19=Bloomfield|first19=Clara D.|title=Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet|journal=Blood|volume=115|issue=3|year=2010|pages=453–474|issn=0006-4971|doi=10.1182/blood-2009-07-235358}}</ref> | ||
* Osteolytic lesions in the ribs, diffuse metaphysical lucency, periostitis with periosteal reaction, and pathologic fractures involving long bones, such as femoral bones, and increase uptake in the involved bones.<ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref> | |||
===Radiographic features:=== | |||
*Using Chest X-ray ('''CXR'''), '''skeletal survey''', '''CT scan''', and '''bone scan''' are: | |||
*Osteolytic lesions in the ribs, diffuse metaphysical lucency, periostitis with periosteal reaction, and pathologic fractures involving long bones, such as femoral bones, and increase uptake in the involved bones.<ref name="AthaleKaste2002">{{cite journal|last1=Athale|first1=Uma H.|last2=Kaste|first2=Sue C.|last3=Razzouk|first3=Bassem I.|last4=Rubnitz|first4=Jeffrey E.|last5=Ribeiro|first5=Raul C.|title=Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia|journal=Journal of Pediatric Hematology/Oncology|volume=24|issue=7|year=2002|pages=561–565|issn=1077-4114|doi=10.1097/00043426-200210000-00014}}</ref> | |||
==References== | ==References== |
Revision as of 04:10, 17 April 2021
Acute megakaryoblastic leukemia Microchapters |
Differentiating Acute megakaryoblastic leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Acute megakaryoblastic leukemia other diagnostic studies On the Web |
American Roentgen Ray Society Images of Acute megakaryoblastic leukemia other diagnostic studies |
FDA on Acute megakaryoblastic leukemia other diagnostic studies |
CDC on Acute megakaryoblastic leukemia other diagnostic studies |
Acute megakaryoblastic leukemia other diagnostic studies in the news |
Blogs on Acute megakaryoblastic leukemia other diagnostic studies |
Directions to Hospitals Treating Acute megakaryoblastic leukemia |
Risk calculators and risk factors for Acute megakaryoblastic leukemia other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Other Diagnostic Studies
- In adults, the features include
- Pancytopenia with low blast counts in the blood
- Myelofibrosis
- An absence of lymphadenopathy and hepatosplenomegaly
- Poor response to chemotherapy,and short clinical course.
- In children, the same clinical presentation but with variable course especially in very young children; both leukocytosis and organomegaly may be present in children with M7. Complete remission and long term survival are more common in children than adults.
- The morphology of cells was observed by means of Bone marrow smear
- The immunophenotype was detected by flow cytometry and immunohistochemistry assay.[1]
- In blood and bone marrow smears megakaryoblasts are usually medium sized to large cells with a high nuclear- cytoplasmic ratio. Nuclear chromatin is dense and homogeneous. There is scanty, variable basophilic cytoplasm which may be vacuolated. An irregular cytoplasmic border is often noted in some of the megakaryoblasts and occasionally projections resembling budding atypical platelets are present. The megakaryoblasts lack myeloperoxidase activity and stain negatively with Sudan black B (SBB).
- They are alpha naphthyl butyrate esterase negative and manifest variable alpha naphthyl acetate esterase activity usually in scattered clumps or granules in the cytoplasm. PAS staining also varies from negative to focal or granular positivity, to strongly positive staining.
- A marrow aspirate is difficult to obtain in many cases because of variable degree of myelofibrosis.
- More precise identification by immunophenotyping or with electron microscopy (EM). Immunophenotyping using MoAb to megakaryocyte restricted antigen (CD41 and CD61) may be diagnostic.[2]
Karyotype analysis:
- It helps in distinguishing due to alter karyotypic presentation (t(1;22)(p13;q13).[3]
Radiographic features:
- Using Chest X-ray (CXR), skeletal survey, CT scan, and bone scan are:
- Osteolytic lesions in the ribs, diffuse metaphysical lucency, periostitis with periosteal reaction, and pathologic fractures involving long bones, such as femoral bones, and increase uptake in the involved bones.[4]
References
- ↑ Lei Q, Liu Y, Tang SQ (2007). "[Childhood acute megakaryoblastic leukemia]". Zhongguo Shi Yan Xue Ye Xue Za Zhi (in Chinese). 15 (3): 528–32. PMID 17605859.
- ↑ Vardiman JW, Harris NL, Brunning RD (2002). "The World Health Organization (WHO) classification of the myeloid neoplasms". Blood. 100 (7): 2292–302. doi:10.1182/blood-2002-04-1199. PMID 12239137.
- ↑ Döhner, Hartmut; Estey, Elihu H.; Amadori, Sergio; Appelbaum, Frederick R.; Büchner, Thomas; Burnett, Alan K.; Dombret, Hervé; Fenaux, Pierre; Grimwade, David; Larson, Richard A.; Lo-Coco, Francesco; Naoe, Tomoki; Niederwieser, Dietger; Ossenkoppele, Gert J.; Sanz, Miguel A.; Sierra, Jorge; Tallman, Martin S.; Löwenberg, Bob; Bloomfield, Clara D. (2010). "Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet". Blood. 115 (3): 453–474. doi:10.1182/blood-2009-07-235358. ISSN 0006-4971.
- ↑ Athale, Uma H.; Kaste, Sue C.; Razzouk, Bassem I.; Rubnitz, Jeffrey E.; Ribeiro, Raul C. (2002). "Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia". Journal of Pediatric Hematology/Oncology. 24 (7): 561–565. doi:10.1097/00043426-200210000-00014. ISSN 1077-4114.